Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study.

IF 2.1 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of General Medicine Pub Date : 2025-06-03 eCollection Date: 2025-01-01 DOI:10.2147/IJGM.S525638

Chenfei Zhang, Xiaoling Huang, Mailidan Maimaitiniyazi, Tingwei Zhou

{"title":"Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study.","authors":"Chenfei Zhang, Xiaoling Huang, Mailidan Maimaitiniyazi, Tingwei Zhou","doi":"10.2147/IJGM.S525638","DOIUrl":null,"url":null,"abstract":"Objective: To compare the efficacy and safety of vedolizumab plus glucocorticoids versus infliximab in severe ulcerative colitis for optimized treatment selection.Methods: Patients admitted to the Department of Gastroenterology of Xinjiang Uygur Autonomous Region People's Hospital with confirmed diagnosis of ulcerative colitis from January 2020 to December 2022 were collected, and according to the biologics used, the patients were divided into Vedolizumab combined with glucocorticoids group (n = 23) and infliximab group (n = 23). Clinically relevant indicators of the patients were retrospectively analyzed.Results: The difference between the basic information of the two groups of patients before treatment was not significant (p > 0.05). WBC 30 weeks, ESR (6 weeks, 30 weeks), ALB 30 weeks, Hb (6 weeks, 14 weeks, 30 weeks) of the difference between the groups was statistically significant (p < 0.05). WBC, CRP, ESR, ALB, Hb were tested by ANOVA, the differences between groups were statistically significant (p < 0.05). Comparison of the incidence of various complications between the two groups of patients, the difference was not significant (p > 0.05). The clinical response rate, clinical remission rate and mucosal healing rate of the 2 groups were statistically analyzed in terms of treatment effects at weeks 6, 14 and 30, respectively. Comparison between the groups showed that the differences in clinical response rate at week 6, clinical remission rate and endoscopic remission rate at week 30 and at weeks 14 and 30 were not statistically significant (p > 0.05); at weeks 14 and 30, the clinical response rate of group A was better than that of group B, and the differences were statistically significant (p < 0.05). At week 14, the clinical remission rate of group A was better than that of group B, and the difference was statistically significant (p < 0.05).Conclusion: Vedolizumab and infliximab are effective for severe UC, but vedolizumab with glucocorticoids outperforms infliximab in clinical response, remission, and long-term outcomes.","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"2839-2849"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145104/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S525638","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To compare the efficacy and safety of vedolizumab plus glucocorticoids versus infliximab in severe ulcerative colitis for optimized treatment selection.

Methods: Patients admitted to the Department of Gastroenterology of Xinjiang Uygur Autonomous Region People's Hospital with confirmed diagnosis of ulcerative colitis from January 2020 to December 2022 were collected, and according to the biologics used, the patients were divided into Vedolizumab combined with glucocorticoids group (n = 23) and infliximab group (n = 23). Clinically relevant indicators of the patients were retrospectively analyzed.

Results: The difference between the basic information of the two groups of patients before treatment was not significant (p > 0.05). WBC 30 weeks, ESR (6 weeks, 30 weeks), ALB 30 weeks, Hb (6 weeks, 14 weeks, 30 weeks) of the difference between the groups was statistically significant (p < 0.05). WBC, CRP, ESR, ALB, Hb were tested by ANOVA, the differences between groups were statistically significant (p < 0.05). Comparison of the incidence of various complications between the two groups of patients, the difference was not significant (p > 0.05). The clinical response rate, clinical remission rate and mucosal healing rate of the 2 groups were statistically analyzed in terms of treatment effects at weeks 6, 14 and 30, respectively. Comparison between the groups showed that the differences in clinical response rate at week 6, clinical remission rate and endoscopic remission rate at week 30 and at weeks 14 and 30 were not statistically significant (p > 0.05); at weeks 14 and 30, the clinical response rate of group A was better than that of group B, and the differences were statistically significant (p < 0.05). At week 14, the clinical remission rate of group A was better than that of group B, and the difference was statistically significant (p < 0.05).

Conclusion: Vedolizumab and infliximab are effective for severe UC, but vedolizumab with glucocorticoids outperforms infliximab in clinical response, remission, and long-term outcomes.

查看原文本刊更多论文

Vedolizumab联合糖皮质激素与英夫利昔滨治疗严重溃疡性结肠炎的疗效和安全性：一项回顾性研究

目的：比较维多单抗联合糖皮质激素与英夫利昔单抗治疗严重溃疡性结肠炎的疗效和安全性，以优化治疗方案的选择。方法：收集2020年1月至2022年12月在新疆维吾尔自治区人民医院消化内科确诊为溃疡性结肠炎的患者，根据使用的生物制剂分为Vedolizumab联合糖皮质激素组（n = 23）和英夫利昔单抗组（n = 23）。回顾性分析患者的临床相关指标。结果：两组患者治疗前基本情况比较，差异无统计学意义（p < 0.05）。WBC 30周、ESR（6周、30周）、ALB 30周、Hb（6周、14周、30周）组间差异均有统计学意义（p < 0.05）。WBC、CRP、ESR、ALB、Hb采用方差分析，组间差异均有统计学意义（p < 0.05）。比较两组患者各种并发症的发生率，差异无统计学意义（p < 0.05）。统计分析两组患者在治疗第6周、第14周和第30周的临床有效率、临床缓解率和粘膜愈合率。两组比较，第6周临床缓解率、第30周临床缓解率及内镜下缓解率、第14周、第30周差异均无统计学意义（p < 0.05）；第14、30周时，A组临床有效率优于B组，差异均有统计学意义（p < 0.05）。第14周时，A组临床缓解率优于B组，差异有统计学意义（p < 0.05）。结论：Vedolizumab和英夫利昔单抗对严重UC有效，但Vedolizumab联合糖皮质激素在临床反应、缓解和长期预后方面优于英夫利昔单抗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of General Medicine Medicine-General Medicine

自引率

0.00%

发文量

1113

审稿时长

16 weeks

期刊介绍： The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.